-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Nuocheng Jianhua announced today that the company's Bruton's tyrosine kinase (BTK) inhibitor obutinib for the treatment of multiple sclerosis (MS) clinical trial application (CTA) has been obtained by the Polish authorities and the Ukrainian Ministry of Health and With the approval of the ethics committee, phase II clinical studies will be launched in these two countries soon
This will be a randomized, double-blind, placebo-controlled phase II clinical study to evaluate the use of abutinib in patients with relapsing-remitting multiple sclerosis (RRMS).
According to data released by the Multiple Sclerosis International Federation (MSIF), currently more than 2.
MS is an autoimmune central nervous system disease.
Note: The original text has been deleted
Reference materials:
[1] Data source: Multiple Sclerosis International Federation (MSIF) official website https:// Data source: Frost & Sullivan analysis